Acelyrin (SLRN) said late Thursday it has received an unsolicited indication of interest from Tang Capital Partners-backed Concentra Biosciences to acquire all of its outstanding shares for $3.00 per share in cash, plus a contingent value right to receive 80% of net proceeds from any out-license or disposition of its development programs or intellectual property.
Acelyrin said it agreed Feb. 6 to an all-stock merger with Alumis (ALMS) in a deal expected to close in Q2.
The company said its board is committed to acting in the interests of shareholders and will make a further announcement on the matter "in due course."
Shares of Acelyrin rose more than 12% in recent premarket activity Friday.
Price: 2.45, Change: +0.28, Percent Change: +12.90
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。